Latest Advances in Lung Cancer Research

The researchers hope the findings of ‘ever-changing’ nature of lung cancer could help doctors to tailor treatments for individual patients.

Research study shows pacritinib has the ability to selectively target in squamous cell but does not impact normal glucose metabolism.

New clinical trial shows improved survival rates and reduced risk of recurrence in patients taking a targeted therapy for NSCLC.

67% of small smoke particles in the US are due to human-ignited fires are responsible for degrade air quality, causing respiratory illnesses, and premature death.

Scientists discover how air pollution triggers lung cancer in non-smokers, identifying a pathway where tiny PM2.5 particles “wake up” dormant cancer cells, leading to new prevention and treatment opportunities.

Racial Disparities in Lung Cancer: Research shows racial disparities in treatment and survival between Black and White lung cancer patients.

Diverse workforce in oncology: Improvement of inclusion and equity critical to reducing health disparities in cancer care.

Latest research shows the level of chromosomal abnormality in lung cancer patients may predict their immunotherapy response.

Seeking to expand targeted therapy for lung cancer, Dr. Alice Berger, a recipient of a LCFA lung cancer research grant, has also received a NIH MERIT Award.

Antibody hinders EGFR lung cancer: Johnson&Johnson’s drug shows succes in hindering tumor growth in 74% of lung cancer patients with EGFR mutations.